title: [TNF inhibitors and myelitis: think about it, even lately].
abstract: Anti-TNF medications have been widely used for the treatment of auto-immune disease and new drugs are regularly approved. We report here a case of late myelitis after more than 6 years of adalimumab in a 74-year-old woman treated for rheumatoid polyarthritis.
authors.affiliation: Centre régional de pharmacovigilance Nice Alpes-Côte d'Azur, CHU, Nice, France.
authors.forename: Marie
authors.initials: M
authors.lastname: Stève-Dumont
authors.affiliation: Service de neurologie, CHU, Nice, France.
authors.forename: Mikael
authors.initials: M
authors.lastname: Cohen
authors.affiliation: Service de neurologie, CHU, Nice, France.
authors.forename: Christine
authors.initials: C
authors.lastname: Lebrun-Frenay
authors.affiliation: Centre régional de pharmacovigilance Nice Alpes-Côte d'Azur, CHU, Nice, France.
authors.forename: Fanny
authors.initials: F
authors.lastname: Rocher
mesh_terms: D000068879:Adalimumab; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D057210:Delayed Diagnosis; D005260:Female; D006801:Humans; D009187:Myelitis / Q000139:chemically induced* / Q000175:diagnosis*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab